CPX-351 Improved Survival in Older Patients With High-Risk Secondary AML
June 5th 2016CPX-351, a liposomal formulation of cytarabine and daunorubicin, improved event-free survival, overall survival, and response compared with a traditional dose of cytarabine/daunorubicin in older patients with high-risk secondary acute myeloid leukemia.